Literature DB >> 23313965

Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma.

Virginia Hernandez-Gea1, Sara Toffanin, Scott L Friedman, Josep M Llovet.   

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver tumor and the third greatest cause of cancer-related death worldwide, and its incidence is increasing. Despite the significant improvement in management of HCC over the past 30 years, there are no effective chemoprevention strategies, and only one systemic therapy has been approved for patients with advanced tumors. This drug, sorafenib, acts on tumor cells and the stroma. HCC develops from chronically damaged tissue that contains large amounts of inflammation and fibrosis, which also promote tumor progression and resistance to therapy. Increasing our understanding of how stromal components interact with cancer cells and the signaling pathways involved could help identify new therapeutic and chemopreventive targets.
Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23313965      PMCID: PMC3578068          DOI: 10.1053/j.gastro.2013.01.002

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  148 in total

1.  Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients.

Authors:  Masahiro Okamoto; Tohru Utsunomiya; Shigeki Wakiyama; Masaji Hashimoto; Kengo Fukuzawa; Takahiro Ezaki; Taizo Hanai; Hiroshi Inoue; Masaki Mori
Journal:  Ann Surg Oncol       Date:  2006-05-23       Impact factor: 5.344

Review 2.  Understanding the "lethal" drivers of tumor-stroma co-evolution: emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment.

Authors:  Michael P Lisanti; Ubaldo E Martinez-Outschoorn; Barbara Chiavarina; Stephanos Pavlides; Diana Whitaker-Menezes; Aristotelis Tsirigos; Agnieszka Witkiewicz; Zhao Lin; Renee Balliet; Anthony Howell; Federica Sotgia
Journal:  Cancer Biol Ther       Date:  2010-09-19       Impact factor: 4.742

3.  Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.

Authors:  Guobin He; Guann-Yi Yu; Vladislav Temkin; Hisanobu Ogata; Christian Kuntzen; Toshiharu Sakurai; Wolfgang Sieghart; Markus Peck-Radosavljevic; Hyam L Leffert; Michael Karin
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

Review 4.  Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress.

Authors:  Helmut K Seitz; Felix Stickel
Journal:  Biol Chem       Date:  2006-04       Impact factor: 3.915

Review 5.  Resection and liver transplantation for hepatocellular carcinoma.

Authors:  Josep M Llovet; Myron Schwartz; Vincenzo Mazzaferro
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

6.  Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice.

Authors:  Marie Anson; Anne-Marie Crain-Denoyelle; Véronique Baud; Fanny Chereau; Angélique Gougelet; Benoit Terris; Satoshi Yamagoe; Sabine Colnot; Mireille Viguier; Christine Perret; Jean-Pierre Couty
Journal:  J Clin Invest       Date:  2012-01-17       Impact factor: 14.808

7.  New strategies in hepatocellular carcinoma: genomic prognostic markers.

Authors:  Augusto Villanueva; Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Clara Alsinet; Radoslav Savic; Helena Cornella; Josep M Llovet
Journal:  Clin Cancer Res       Date:  2010-08-16       Impact factor: 12.531

8.  HAb18G/CD147 functions in invasion and metastasis of hepatocellular carcinoma.

Authors:  Jing Xu; Hui-Yun Xu; Qing Zhang; Fei Song; Jian-Li Jiang; Xiang-Min Yang; Li Mi; Ning Wen; Rong Tian; Li Wang; Hui Yao; Qiang Feng; Yang Zhang; Jin-Liang Xing; Ping Zhu; Zhi-Nan Chen
Journal:  Mol Cancer Res       Date:  2007-06       Impact factor: 5.852

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  A lymphotoxin-driven pathway to hepatocellular carcinoma.

Authors:  Johannes Haybaeck; Nicolas Zeller; Monika Julia Wolf; Achim Weber; Ulrich Wagner; Michael Odo Kurrer; Juliane Bremer; Giandomenica Iezzi; Rolf Graf; Pierre-Alain Clavien; Robert Thimme; Hubert Blum; Sergei A Nedospasov; Kurt Zatloukal; Muhammad Ramzan; Sandra Ciesek; Thomas Pietschmann; Patrice N Marche; Michael Karin; Manfred Kopf; Jeffrey L Browning; Adriano Aguzzi; Mathias Heikenwalder
Journal:  Cancer Cell       Date:  2009-10-06       Impact factor: 31.743

View more
  264 in total

1.  CCL18/PITPNM3 enhances migration, invasion, and EMT through the NF-κB signaling pathway in hepatocellular carcinoma.

Authors:  Zeyu Lin; Wenbin Li; Heyun Zhang; Wei Wu; Yaorong Peng; Yunjie Zeng; Yunle Wan; Jie Wang; Nengtai Ouyang
Journal:  Tumour Biol       Date:  2015-10-08

2.  Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.

Authors:  Jia-Yu Liu; Tsaiyu Chiang; Chun-Hung Liu; Guann-Gen Chern; Ts-Ting Lin; Dong-Yu Gao; Yunching Chen
Journal:  Mol Ther       Date:  2015-08-17       Impact factor: 11.454

3.  Validation of a Liver Index and Its Significance for HCC Aggressiveness.

Authors:  Brian I Carr; Vito Guerra
Journal:  J Gastrointest Cancer       Date:  2017-09

Review 4.  Hepatocellular carcinoma.

Authors:  Marie-Annick Buendia; Christine Neuveut
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-02       Impact factor: 6.915

5.  CCR6+ B lymphocytes responding to tumor cell-derived CCL20 support hepatocellular carcinoma progression via enhancing angiogenesis.

Authors:  Huan He; Jianxiong Wu; Mengya Zang; Weihu Wang; Xiuli Chang; Xiangmei Chen; Ruijun Wang; Zhiyuan Wu; Liming Wang; Dongmei Wang; Fengmin Lu; Zongtang Sun; Chunfeng Qu
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

6.  In situ gelling silk-elastinlike protein polymer for transarterial chemoembolization.

Authors:  Azadeh Poursaid; Robert Price; Andrea Tiede; Erik Olson; Eugene Huo; Lawrence McGill; Hamidreza Ghandehari; Joseph Cappello
Journal:  Biomaterials       Date:  2015-04-28       Impact factor: 12.479

7.  Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatment in vitro.

Authors:  Sebastian Buschauer; Andreas Koch; Philipp Wiggermann; Martina Müller; Claus Hellerbrand
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

8.  Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.

Authors:  Kohei Shigeta; Meenal Datta; Tai Hato; Shuji Kitahara; Ivy X Chen; Aya Matsui; Hiroto Kikuchi; Emilie Mamessier; Shuichi Aoki; Rakesh R Ramjiawan; Hiroki Ochiai; Nabeel Bardeesy; Peigen Huang; Mark Cobbold; Andrew X Zhu; Rakesh K Jain; Dan G Duda
Journal:  Hepatology       Date:  2019-10-14       Impact factor: 17.425

9.  Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Semin Liver Dis       Date:  2020-04-02       Impact factor: 6.115

Review 10.  Functional and genetic deconstruction of the cellular origin in liver cancer.

Authors:  Jens U Marquardt; Jesper B Andersen; Snorri S Thorgeirsson
Journal:  Nat Rev Cancer       Date:  2015-11       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.